Stockscreener 앱 받기
31.82
1.64%
-0.56
전일 마감가:
$32.38
열려 있는:
$31.96
하루 거래량:
126.04K
Relative Volume:
0.41
시가총액:
$1.60B
수익:
$357.71M
순이익/손실:
$-20.10M
주가수익비율:
-76.93
EPS:
-0.4136
순현금흐름:
$28.67M
1주 성능:
-5.63%
1개월 성능:
-6.90%
6개월 성능:
+4.56%
1년 성능:
+2.18%
1일 변동 폭
$31.33
$32.50
1주일 범위
$31.33
$34.50
52주 변동 폭
$23.15
$39.33
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
IMCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
31.80 | 1.63B | 357.71M | -20.10M | 28.67M | -0.4136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.71 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.74 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.50 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
830.64 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.63 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Wells Fargo | Overweight |
| 2025-09-18 | 재개 | Guggenheim | Neutral |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-05-27 | 개시 | Deutsche Bank | Buy |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $60.89 - Defense World
State of New Jersey Common Pension Fund D Purchases New Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Y Intercept Hong Kong Ltd Makes New $1.62 Million Investment in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Growth Picks: 3 Low-Cost Stocks That Could Double in Value - Investing.com
Immunocore (NASDAQ:IMCR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
TD Asset Management Inc Sells 9,590 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stocks Showing Improved Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
Goldman Sachs Group Inc. Sells 4,782 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - Defense World
Embracer Group AB (publ) (LON:0GFE) Shares Up 3% – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Insider Sells $803,716.44 in Stock - MarketBeat
Immunocore (NASDAQ:IMCR) Now Covered by Analysts at Guggenheim - Defense World
Vericel (NASDAQ:VCEL) Shares Gap Down on Analyst Downgrade - Defense World
Monument Circle Acquisition (OTCMKTS:MONCU) Shares Down 0.3% – What’s Next? - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.89 Average Price Target from Analysts - MarketBeat
H.C. Wainwright reaffirms Buy rating on Immunocore stock, maintains $100 target - Investing.com
Green Energy Stocks Worth Watching – September 12th - Defense World
Cubist Systematic Strategies LLC Reduces Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Hold” by Analysts - Defense World
Banque Transatlantique SA Acquires Shares of 10,150 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Baker BROS. Advisors LP Has $68.91 Million Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Stellar AfricaGold (CVE:SPX) Shares Up 25.8% – What’s Next? - Defense World
Frazier Life Sciences Management L.P. Has $8.94 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects - Investing.com India
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects By Investing.com - Investing.com South Africa
Immunocore Holdings plc ADR (NASDAQ: IMCR) Rises 9.33% In Recent Trading, What’s Next? - stocksregister.com
Emergent Biosolutions Inc. $EBS Holdings Trimmed by Invesco Ltd. - Defense World
Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Jefferies assumes coverage on Immunocore stock with Buy rating, $48 target - Investing.com
Earnings call transcript: Immunocore Q2 2025 beats revenue forecast - Investing.com
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.00 Consensus Price Target from Brokerages - Defense World
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
Is Rising Revenue and Narrowing Losses Altering the Investment Case for Immunocore Holdings (IMCR)? - Sahm
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - sharewise.com
Immunocore stock price target raised to $36 from $33 at Mizuho - Investing.com
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤노코어 홀딩스 주식 (IMCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Sep 30 '25 |
Sale |
35.23 |
61,849 |
2,178,940 |
0 |
| Berman David M | HEAD OF R&D |
Sep 12 '25 |
Option Exercise |
17.46 |
22,532 |
393,409 |
22,532 |
| Berman David M | HEAD OF R&D |
Sep 15 '25 |
Option Exercise |
17.46 |
200 |
3,492 |
200 |
| Berman David M | HEAD OF R&D |
Sep 12 '25 |
Sale |
35.67 |
22,532 |
803,699 |
0 |
| Berman David M | HEAD OF R&D |
Sep 15 '25 |
Sale |
35.01 |
200 |
7,002 |
0 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Option Exercise |
17.46 |
31,338 |
547,161 |
31,338 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Option Exercise |
17.46 |
19,081 |
333,154 |
19,081 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Sale |
36.14 |
31,338 |
1,132,709 |
0 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Sale |
36.28 |
19,081 |
692,259 |
0 |
1.29%
0.56%
자본화:
|
볼륨(24시간):